Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference
January 31, 2023 08:00 ET
|
Rain Oncology Inc.
NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology
January 23, 2023 08:00 ET
|
Rain Oncology Inc.
– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in...
Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.
December 29, 2022 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead...
Rain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care Conference
December 27, 2022 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
August 04, 2022 08:00 ET
|
Rain Therapeutics
– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance – – MANTRA topline data anticipated in 1H 2023 – – Management to host 2Q 2022 Earnings Call today at 5:00 PM...
Rain Therapeutics to Report Second Quarter 2022 Financial Results and Highlights of Recent Progress on August 4, 2022
July 21, 2022 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report...
Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2022 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics, today announced it...
Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Recent Progress on May 4, 2022
April 20, 2022 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report...
Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 01, 2022 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster...
Rain Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Highlights of Recent Progress on March 3, 2022
February 24, 2022 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report...